Home/Pipeline/Pan-KRAS Inhibitors

Pan-KRAS Inhibitors

Oncology

PreclinicalPartnered

Key Facts

Indication

Oncology

Phase

Preclinical

Status

Partnered

Company

Redx Pharma

About Redx Pharma

Redx Pharma is a focused, AIM-listed biotech with a mission to translate innovative science into novel treatments for fibrosis and cancer. The company has achieved key milestones, including Fast Track designation for its lead GI-restricted ROCK inhibitor (RXC008) and reporting Phase 2a data for its systemic ROCK2 inhibitor, zelasudil (RXC007). Its strategy centers on a proprietary drug discovery platform, a balanced pipeline of proprietary and partnered assets, and a clear path to value inflection through clinical data readouts and strategic partnerships.

View full company profile

Therapeutic Areas

Fibrotic Diseases Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active